Acumen Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025
Acumen Pharmaceuticals (NASDAQ: ABOS), a clinical-stage biopharmaceutical company focused on developing treatments for Alzheimer's disease, has scheduled its first quarter 2025 financial results announcement for May 13, 2025. The company will host a conference call and webcast at 8:00 a.m. ET to discuss business updates and financial performance. Participants must pre-register for the conference call at least one day in advance. The webcast will be accessible through the company's website and will remain available for a minimum of 30 days in the Investors section.
Acumen Pharmaceuticals (NASDAQ: ABOS), una società biofarmaceutica in fase clinica specializzata nello sviluppo di trattamenti per la malattia di Alzheimer, ha programmato l'annuncio dei risultati finanziari del primo trimestre 2025 per il 13 maggio 2025. La società terrà una conference call e una trasmissione web alle 8:00 a.m. ET per discutere aggiornamenti aziendali e performance finanziaria. I partecipanti devono registrarsi in anticipo almeno un giorno prima della conference call. La trasmissione web sarà accessibile tramite il sito web della società e resterà disponibile per almeno 30 giorni nella sezione Investitori.
Acumen Pharmaceuticals (NASDAQ: ABOS), una compañía biofarmacéutica en etapa clínica enfocada en desarrollar tratamientos para la enfermedad de Alzheimer, ha programado el anuncio de sus resultados financieros del primer trimestre de 2025 para el 13 de mayo de 2025. La empresa realizará una llamada conferencia y una transmisión en vivo a las 8:00 a.m. ET para discutir actualizaciones comerciales y desempeño financiero. Los participantes deben registrarse con al menos un día de anticipación para la llamada conferencia. La transmisión estará disponible a través del sitio web de la empresa y permanecerá accesible por un mínimo de 30 días en la sección de Inversionistas.
Acumen Pharmaceuticals (NASDAQ: ABOS)는 알츠하이머병 치료제 개발에 주력하는 임상 단계 바이오제약 회사로, 2025년 1분기 재무 실적 발표를 2025년 5월 13일에 예정하고 있습니다. 회사는 동부 표준시 오전 8시에 비즈니스 업데이트 및 재무 성과를 논의하기 위한 컨퍼런스 콜과 웹캐스트를 진행할 예정입니다. 참가자는 컨퍼런스 콜 최소 하루 전에 사전 등록해야 합니다. 웹캐스트는 회사 웹사이트를 통해 시청할 수 있으며 투자자 섹션에서 최소 30일간 제공됩니다.
Acumen Pharmaceuticals (NASDAQ: ABOS), une société biopharmaceutique en phase clinique spécialisée dans le développement de traitements contre la maladie d'Alzheimer, a programmé l'annonce de ses résultats financiers du premier trimestre 2025 pour le 13 mai 2025. La société tiendra une conférence téléphonique et une diffusion en direct à 8h00 ET pour discuter des mises à jour commerciales et des performances financières. Les participants doivent s'inscrire au moins un jour avant la conférence téléphonique. La diffusion sera accessible via le site web de la société et restera disponible pendant au moins 30 jours dans la section Investisseurs.
Acumen Pharmaceuticals (NASDAQ: ABOS), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung von Behandlungen für Alzheimer konzentriert, hat die Bekanntgabe der Finanzergebnisse für das erste Quartal 2025 für den 13. Mai 2025 geplant. Das Unternehmen wird eine Telefonkonferenz und einen Webcast um 8:00 Uhr ET abhalten, um Geschäftsaktualisierungen und finanzielle Leistungen zu besprechen. Teilnehmer müssen sich mindestens einen Tag vor der Telefonkonferenz anmelden. Der Webcast ist über die Unternehmenswebsite zugänglich und bleibt für mindestens 30 Tage im Investorenbereich verfügbar.
- None.
- None.
NEWTON, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, today announced that the Company will report first quarter 2025 financial results on Tuesday, May 13, 2025. The Company will host a conference call and live audio webcast at 8:00 a.m. ET to provide a business and financial update.
To participate in the live conference call, please register using this link. After registration, you will be informed of the dial-in numbers including PIN. Please register at least one day in advance.
The webcast audio will be available via this link.
An archived version of the webcast will be available for at least 30 days in the Investors section of the Company's website at www.acumenpharm.com.
About Acumen Pharmaceuticals, Inc.
Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD). Acumen’s scientific founders pioneered research on AβOs, which a growing body of evidence indicates are early and persistent triggers of Alzheimer’s disease pathology. Acumen is currently focused on advancing its investigational product candidate, sabirnetug (ACU193), a humanized monoclonal antibody that selectively targets toxic soluble AβOs, in its ongoing Phase 2 clinical trial ALTITUDE-AD (NCT06335173) in early symptomatic Alzheimer’s disease patients, following positive results in its Phase 1 trial INTERCEPT-AD. The company is headquartered in Newton, Mass. For more information, visit www.acumenpharm.com.
Investors:
Alex Braun
abraun@acumenpharm.com
Media:
AcumenPR@westwicke.com
FAQ
When will Acumen Pharmaceuticals (ABOS) report Q1 2025 earnings?
What time is the ABOS Q1 2025 earnings call?
How can I access Acumen Pharmaceuticals' Q1 2025 earnings call?
What is Acumen Pharmaceuticals' main focus in drug development?
